Related Experiment Video

Updated: Jun 5, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations

Katherine Lynn Youmans1, Steffi Leung, Juan Zhang

  • 1Dept of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL 60612, United States. kyouma2@uic.edu

Journal of Neuroscience Methods
|January 12, 2011
PubMed

Insights

Researchers optimized protein extraction methods to study amyloid-beta 42 (Aβ42) and apolipoprotein E (apoE) in Alzheimer

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaques, with soluble amyloid-beta 42 (Aβ42) and intraneuronal Aβ42 being key drivers of neurotoxicity.
  • Apolipoprotein E (apoE) influences AD pathogenesis, and the apoE ɛ4 allele is a major genetic risk factor.
  • Understanding the solubility and extraction profiles of Aβ42 and apoE is crucial for studying AD progression.

Purpose of the Study:

  • To optimize protein extraction protocols for analyzing Aβ42 and apoE in the context of varying Alzheimer's disease pathology.
  • To characterize the 5xFAD-mouse-specific extraction profile for Aβ42 and its relationship with membrane-associated apoE (m-apoE).
  • To investigate age-dependent changes in Aβ42 and m-apoE solubility in different brain regions.

Main Methods:

  • Sequential protein extractions using TBS, TBSX, GuHCl, and FA on brain tissue from young and old wild-type (WT) and 5xFAD mice.
  • Analysis of Aβ42 and m-apoE solubility across different extraction fractions and brain regions (cortex, hippocampus).
  • Validation of extraction specificity for soluble and membrane-associated proteins.

Main Results:

  • Formic acid (FA) extraction increased insoluble Aβ42 and m-apoE recovery in older 5xFAD mice compared to guanidine-HCl (GuHCl).
  • Aβ42 was found to be TBS- or GuHCl-soluble in both young and old 5xFAD mice.
  • While m-apoE is TBSX-soluble in WT mice, it becomes TBS- or GuHCl-soluble in 5xFAD mice, indicating a parallel extraction profile with Aβ42.

Conclusions:

  • The 5xFAD mouse model exhibits an accelerated AD-like pathology with distinct Aβ42 and m-apoE extraction profiles.
  • The optimized extraction method successfully differentiates soluble and insoluble Aβ42 and m-apoE, reflecting neuropathological changes.
  • This characterized method provides a valuable tool for studying disease-relevant apoE and Aβ in both normal and pathological brain states.

More Related Videos

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...